Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins | Contract Pharma

What are you searching for?

Sign in
Breaking News

EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

State-of-the-art manufacturing equipment to double overall prostaglandin capacity of the Budapest site by 2027.

By: Anthony Vecchione

EUROAPI, a company focused on reinventing active ingredient solutions, announced a €50 million investment for the installation of a new state-of-the-art production plant at its Budapest site. The project will be focused on the debottlenecking of the current capacity and the construction of new multi-purpose manufacturing equipment that will more than double the overall prostaglandin capacity of the Budapest site by 2027 in two phases: 2023-2025 (approximately 2/3 of the total investment) and 2026-2027.

Prostaglandin is one of the most dynamic components of the active pharmaceutical ingredient (API) market, with a ~€5 billion annual drug product sales market, expected to grow at 5-7% annually (CAGR1) between 2022 and 2027.

In a statement, EUROAPI said that it is the only Western supplier with a complete portfolio of prostaglandins and a fully integrated production site located in Europe. The project aims to bolster EUROAPI’s Hungarian operations and reinforce the company’s commitment to serving the needs of its clients in differentiated segments of health products.

“EUROAPI is positioned as the only Western prostaglandin supplier with a complete prostaglandin portfolio and a fully backward-integrated production located in the heart of Europe,” said Karl Rotthier, CEO of EUROAPI. “This key investment in Budapest will enable us to increase our productivity and meet the growing demand in a dynamic prostaglandin market, growing at 5-7% per annum.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics